Piper Sandler Maintains Overweight on AbbVie, Raises Price Target to $303

Benzinga · 1d ago
Piper Sandler analyst David Amsellem maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $298 to $303.